Bernard Maybury

I'm bewildered we ever started giving pegfilgrastim at 24hrs. See some crazy early neutrophilias and disabling pain. We never gave regular GCSF this early

@houndcl was the first and major whistleblower for the Time-of-day @naturemedicine paper, which resulted in significant investigations across biomedical field and subsequent editorial actions for the paper This had major impacts in saving research fundings and patient outcome. But in return @houndcl was banned from X Can @elonmusk and @nikitabier please look into this? And can big BioX & academic accounts please help retweeting for awareness too? #freehoundcl

Very proud of our group today and especially Andrew Challenger's work looking at excess mortality in DLBCL patients- which persists even beyond 10 years from diagnosis. Needs to be considered in our trial designs! @DavidJCutter @graham74GC doi.org/10.1182/blooda…

Clinical Proof of concept for p53 reactivation in TP53 Y220C mutated cancers nejm.org/doi/full/10.10…

In 1999, Tom Maniatis discovered something remarkable: neurons achieve self-avoidance via stochastic methylation of the protocadherin gene cluster. We've just discovered this locus is an evolvable in-vivo barcode across the human tissues: biorxiv.org/cgi/content/sh… 🧵

access to an anti-CD20/CD3 bispecific in routine clinical care in the UK - finally following @NICEComms approval of epcoritimab #FL #lymsm

Impact of graft‐versus‐host disease prophylaxis strategies on GvHD‐free/relapse‐free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score‐matched analysis onlinelibrary.wiley.com/doi/abs/10.111…

@AnilMakam And yet, I share the scepticism

something doesn't add up with this trial it's too good to be true if there was a polymarket, I'd wager it doesn't replicate

@AnilMakam And in CAR T ashpublications.org/blood/article-… and pmc.ncbi.nlm.nih.gov/articles/pmid/…

@AnilMakam And a subsequent study from elsewhere jitc.bmj.com/content/13/12/…

@AnilMakam In stem cell allograft there's this dx.doi.org/10.1016/j.cell…

Tune in as Dr Charles Percy breaks down the new joint BSH–UKHCDO Guideline on acquired coagulation factor inhibitors. A clear, practical conversation about what the 2025 guidance means for clinical practice. bit.ly/45KnAbV

@EvidenceRounds This is dubious. Cohort is were defined by DLBCL. IRL prior to biopsy, we don't know what kind of lymphoma they have, or even if they have lymphoma, so doesn't inform practice. Also, in the <50 pts who received steroids, twice as many had necrotic, non-diagnostic first biopsies

Prebiopsy steroids don’t reduce diagnostic yield in lymphoma (DLBCL) A retrospective study confirmed biopsy type mattered most for yield (excisional > core >>> FNA)

Great work by Dan Hodson's lab and colleagues demonstrating the utility and feasibility of ctDNA in LBCL, congratulations to all those involved!

Delighted to share initial results of the CRUK ph I/II trial of aleta 001, a 1st in class CAR T engager protein at #ASH2025 ✅ Excellent safety profile ✅ No DLTs ✅ No SAEs beyond gr1 CRS ✅ Robust and sustained CAR T expansions @BioAleta @PDRennert @immunologydoc @uhbtrust

Fantastic talk today by Vaishali Dulobdas at #ASH2025 on effect of immune parameters and IgRT on post CD19 CAR T outcomes. #lymsm #uhbtrust #nickduncan31 @Capt__Kirkwood @immunologydoc @lymphomule @CCHBham @Paneeshas @lymphomahub @DrLindsayG

Impact of IVIG on post-CAR survival #ASH25 - 430 pts, most LBCL & axicel - low IgA at 1 & 3 mos = increased NRM at all timepoints - low baseline IgM = worse PFS/OS - 20% got IVIG: no effect on NRM! No impact of IgG on survival! Provocative & supports selective use of IVIG. #lymsm

Sorry but I fail to see how what price the NHS pays for drugs (prices that the companies agreed to), leads to reduced investment in UK by pharma. Total BS. The two are not linked. R&D is a global business, UK sales is small fry.

I've been reporting in East Africa on the impact of President Trump's USAID cuts, and I find that not only are children dying in large numbers but the pace is accelerating as stockpiles run out and people grow weaker. I also obtained an internal Trump administration memo stating that the cost of shutting down USAID is $6.4 billion over two years. That sum could save more than 1 million children's lives; instead, it is being spent to to shut down programs that save lives. Help spread the word. nytimes.com/2025/09/20/opi…

Medical Imaging and Pediatric and Adolescent Haem cancer Risk During 35,715,325 person-yrs of f/up (mean, 10.1 yrs/person) 2961 Haem CA diag primarily lymphoid CA: 79.3% 10.1% (95% CI, 5.8 to 14.2) of hem ca may have been attrib to radiation exposure from medical imaging @NEJM